Devonian reports C$1.9 million quarterly loss, cash falls to C$0.7 million

The Quebec biopharmaceutical company said it remains debt-free as it prioritizes Thykamine for radiodermatitis prevention, pediatric atopic dermatitis and studies in MASH and fibrotic diseases.

Summary

verifying reliability

Terms & Concepts

No specialized terms available for this topic.